The problem of adherence to therapy in chronic myeloid leukemia: understanding the patient and making a decision

E.Yu. Chelysheva1, A.V. Galaktionova2, and A.G. Turkina1

1 Hematology Research Center, RF Ministry of Health, Moscow, Russian Federation

2 ANO “CO-operation project”, Moscow, Russian Federation


ABSTRACT

This article prepared by hematologists and the psychologist raises the problem of adherence to therapy in chronic myeloid leukemia. Poor adherence to therapy can worsen treatment outcomes. Patients who take less than 90 % of prescribed imatinib have lower chances to achieve clinically significant deep remission. It is shown that adherence rates decrease over time. Methods for measurement of adherence have limitations and do not always reflect an actual situation. It is noted that long-term treatment using medication in a form of tablets has its peculiarities associated with the necessity of a patient’s clear understanding of treatment goals, appropriate information on therapy aspects, and correction of side effects. The data on tyrosine kinase inhibitors regimens in chronic myeloid leukemia are included. The causes of poor adherence to therapy related to a particular mode of treatment and psychological status of the patient are described. Practical recommendations on adherence improvement are given.


Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, adherence to therapy

Read in PDF (RUS) pdficon


REFERENCES

  1. Deininger M., O’Brien S.G., Guilhot F. et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood (ASH Annual Meeting Abstracts), 2009; 114(22): 1126.
  2. Туркина А.Г., Челышева Е.Ю., Гусарова Г.А. и др. Программное ле- чение заболеваний системы крови. М.: Практика, 2012: 19–65. [Turkina A.G., Chelysheva E.Yu., Gusarova G.A. i dr. Programmnoye lecheniye zabolevaniy sistemy krovi (Program management of hematological disorders). M.: Practika, 2012: 19–65.]
  3. Baccarani M., Cortes J., Pane F. et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. J. Clin. Oncol. 2009; 27(35): 6041–51.
  4. Baccarani M., Pileri S., Steegmann J.-L. et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23(Suppl. 7): vii72–vii77.
  5. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action, 2003. Available at: http://whqlibdoc.who.int/publications/2003/9241545992.pdf.
  6. Noens L., van Lierde M.-A., De Bock R. et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401–11.
  7. Yood M.U., Oliveria S.A., Hirji I. et al. Adherence to treatment in patients with chronic myelogenous leukemia during a 10-year time period: A medical record review. Blood (ASH Annual Meeting Abstracts) 2010; 116(21): 1235.
  8. Marin D., Bazeos A., Mahon F.-X. et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 2010; 28(14): 2381–8.
  9. Milojkovic D., Apperley J. Mechanisms or resistance to imatinib and second generation tyrosine kinase inhibitors in chronic myeloid leukemia. Clin. Cancer Res. 2009; 15(24): 7519–27.
  10. Куцев С.И., Шатохин Ю.В. Влияние перерывов терапии иматинибом на достижение цитогенетического и молекулярного ответов у больных хроническим миелолейкозом. Казан. мед. журн. 2009; 90(6): 827–31. [Kutsev S.I., Shatokhin Yu.V. Vliyaniye pereryvov terapii imatinibom na dostizheniye tsitogeneticheskogo i molekulyarnogo otvetov u bolnykh chronicheskim miyeloleykozom (Effect of interruptions in imatinib therapy on achievement of molecular response in patients with chronic myeloid leukemia). Kazan. med. zhurn. 2009; 90(6): 827–31.]
  11. Darkow T., Henk H.J., Thomas S.K. et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25(6): 481–96.
  12. Куцев С.И., Оксенюк О.С., Кравченко Е.Г. и др. Лекарственный мониторинг терапии хронического миелолейкоза иматинибом. Клин. онкогематол. 2010: 3(1): 1–9. [Kutsev S.I., Oksenyuk O.S., Kravchenko E.G. i dr. Lekarstvennyy monitoring terapii khronicheskogo miyeloleykoza imatinibom (Drug monitoring of imatinib therapy for chronic myeloid leukemia). Klin. onkogematol. 2010; 3(1): 1–9.]
  13. Ibrahim A.R., Milojkovic D., Bua M. et al. Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy. Blood (ASH Annual Meeting Abstracts) 2010; 116(21): 3414.
  14. Medicines adherence Involving patients in decisions about prescribed medicines and supporting adherence. NICE Clinical Guideline 76, 2009. Available at: http://www.nice.org.uk/nicemedia/live/11766/43042/43042.pdf.
  15. Barber N., Parsons J., Clifford S. et al. Patients’ problems with new medication for chronic conditions. Qual. Saf. Health Care 2004; 13(3): 172–5.
  16. Eliasson L., Clifford S., Barber N. et al. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk. Res. 2011; 35(5): 626–30.
  17. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 2001; 23(8): 1296–310.
  18. da Silveira V.L., Drachler M.L., Leite J.C. et al. Characteristics of HIV antiretroviral regimen and treatment adherence. Braz. J. Infect. Dis. 2003; 7(3): 194–201.
  19. Osterberg L., Blaschke T. Drug Therapy: Adherence to Medication. N. Engl. J. Med. 2005; 353(5): 487–97.
  20. Albert N.M. Improving medication adherence in chronic cardiovascular disease. Crit. Care Nurse 2008; 28(5): 54–64.
  21. Wu J.-R., Moser D.K., Chung M.L. et al. Objectively Measured, but Not Self-Reported, Medication Adherence Independently Predicts Event-Free Survival in Patients With Heart Failure. J. Card. Fail. 2008; 14(3): 203–10.
  22. Paterson D.L., Potoski B., Capitano B. et al. Measurement of adherence to antiretroviral medications. JAIDS 2002; 31(Suppl. 3): S103–6.
  23. Bartlett J.A. Addressing the Challenges of Adherence. JAIDS 2002; 29(Suppl. 2): S2–10.
  24. Andrade S.E., Kahler K.H., Frech F. et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 2006; 15(8): 565–74.
  25. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 2001; 23(8): 1296–310.
  26. Гливек® (иматиниб) — инструкция по применению препарата, 2012. [Glivek® (imatinib) — instruktsiya po primeneniyu preparata (Gleevec® (imatinib) prescribing information), 2012.]
  27. Тасигна® (нилотиниб) — инструкция по применению препарата, 2012. [Tasigna® (nilotinib) — instruktsiya po primeneniyu preparata (Tasigna® (nilotinib) prescribing information), 2012.]
  28. Спрайсел® (дазатиниб) — инструкция по применению препарата, 2012. [Spraysel® (dasatinib) — instruktsiya po primeneniyu preparata (Sprycel® (dasatinib) prescribing information), 2012.]
  29. St. Charles M., Bollu V.K., Hornyak E. et al. Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114(22): 2209.
  30. Hines P., Hirji I., Davis C.C. Concomitant medications and comorbidities among patients with chronic myelogenous leukemia using pharmetrics data. Poster Presented at European Society of Hematology (ESH) — International CML Foundation 12th International Conference; September 24–26, 2010 Washington, DC.
  31. Touchette D.R. Medication compliance, adherence, and persistence: Current status of behavioral and educational interventions to improve outcomes. J. Manag. Care Pharm. 2008; 14(6): S2–10.
  32. Nunes V., Neilson J., O’Flynn N. et al. Clinical guidelines and evidence review for medicines adherence involving patients. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2009.
  33. Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериал. гипертенз. 2004; 10(3): 3. [Konradi A.O., Polunicheva E.V. Nedostatochnaya priverzhennost k lecheniyu arterialnoy gipertenzii: prichiny i puti korrektsii (Poor adherence to therapy of arterial hypertension: causes and ways of correction). Arterial. gipertenz. 2004; 10(3): 3.]
  34. Власюк Т. Приверженность к терапии: в поисках улучшения. Электронное издание. Аптека. № 651 (30) 04.08.2008. http://www.apteka.ua/ online/27333/ [Vlasyuk T. Priverzhennost k terapii: v poiskakh uluchsheniya. Electronnoye izdaniye (Adherence to therapy: in pursuit of improvement. Electronic edition). Apteka. #651 (30) 04.08.2008. http://www.apteka.ua/online/27333/]
  35. Енцов Д.В. Приверженность к терапии. Электронное издание. Меди- цинский справочник. http://doctorspb.ru/articles.php?article_id=1606 [Yentsov D.V. Priverzhennost k terapii. Electronnoye izdaniye. Meditsinskiy spravochnik (Adherence to therapy. Electronic edition. Medical guide). http:// doctorspb.ru/articles.php?article_id=1606]